Press releases

Press releases

17 July 2014  - Paris (France)

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

11 July 2014  - Paris (France)

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe

01 July 2014  - Paris (France)

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

04 June 2014  - Paris (France)

Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014

13 May 2014  - Paris (France)

Ipsen announces a step forward in the resupply of Increlex® in the U.S.

30 April 2014  - Paris (France)

Ipsen’s first quarter 2014 sales

12 April 2014  - Paris (France)

Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul

11 April 2014  - Paris (France)

The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, "Biology viewed through the prism of cancer", attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research

09 April 2014  - Paris (France)

Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext

20 March 2014  - Paris (France)

Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement